GGrantIndex
← Search

Molecular Mechanisms of Cancer

$47,836P30FY2018CANIH

University Of Chicago, Chicago IL

Investigators

Linked publications, trials & patents

Paper 39661064Paper 39579248Paper 39438113Paper 39374047Paper 39270007Paper 39141403Paper 39114540Paper 39108474Paper 39071306Paper 39069988Paper 38883758Paper 38881356Paper 38849889Paper 38810242Paper 38771643Paper 38752924Paper 38735044Paper 38716867Paper 38691450Paper 38632339Paper 38561491Paper 38548994Paper 38536082Paper 38533736Paper 38496521Paper 38427437Paper 38421866Paper 38381713Paper 38294692Paper 38294689Paper 38293065Paper 38219706Paper 38213818Paper 38190286Paper 38186960Paper 38175791Paper 38155245Trial NCT02573363Trial NCT02573220Trial NCT02542202Trial NCT02540876Trial NCT02485535Trial NCT02420210Trial NCT02399371Trial NCT02389517Trial NCT02366819Trial NCT02333188Trial NCT02333162Trial NCT02275533Trial NCT02258659Trial NCT02213913Trial NCT02199665Trial NCT02122172Trial NCT02046421Trial NCT02012296Trial NCT01949740Trial NCT01861301Trial NCT01696955Trial NCT01576172Trial NCT01307618Trial NCT01281176Trial NCT01278615Trial NCT01267266Trial NCT01256385Trial NCT01208051Trial NCT01174264Trial NCT01122888Trial NCT01076543Trial NCT01064622Trial NCT00859937Trial NCT00720174Trial NCT00504153Trial NCT00436579Trial NCT00387335Trial NCT00381641Trial NCT00376688Trial NCT00369551Trial NCT00351975Trial NCT00303862Trial NCT00290472Trial NCT00265798Trial NCT00126542Trial NCT00095784Trial NCT00091026Trial NCT00087373Trial NCT00062075Trial NCT00058019Trial NCT00055913Trial NCT00039416Trial NCT00027703Trial NCT00023946Patent 7192711Patent 6870037Patent 6482934Patent 6387619Patent 6043216Patent 5916752Patent 5786344Patent 5698686Patent 5618917

Abstract

ABSTRACT The overarching goal of the University of Chicago Medicine Comprehensive Cancer Center (UCCCC) Molecular Mechanisms of Cancer (MMC) Program is to identify and characterize molecular mechanisms underlying cancer cell growth and metastasis leading to development of improved treatment options through discovery-based science. To meet these overall objectives, the MMC Program has been organized by its leadership around three key scientific themes: 1) mechanisms of altered gene expression in cancer that encompasses understanding the significance for cancer etiology of genomic rearrangements, context-specific gene expression patterns and altered gene signatures, chromatin modifications and epigenetic marks and RNA biology; 2) mechanisms of transformation and altered cell growth in cancer, that includes analysis of how proliferation, differentiation, metabolism, cell death and autophagy are deregulated in cancers, and the role these processes play in cancer stem cells and therapy responses; and 3) mechanistic analysis of the tumor microenvironment and cancer metastasis, with an emphasis on defining novel mechanisms of altered cell motility, loss of adhesion, extra-cellular matrix control, acquisition of invasiveness, cell-cell signaling in the tumor microenvironment, tumor hypoxia, cancer-associated fibroblasts, and tumor-associated macrophages. The MMC Program consists of 37 faculty members from 14 Departments, including key faculty from the Department of Chemistry. In the current funding period (2013-2016), Program members published 564 cancer-related articles (18% intraprogrammatic, 34% interprogrammatic, and 60% interinstitutional). W2Program members are supported by $8.52 M (direct costs) in peer-reviewed funding, and $2.80 M (direct costs) from the National Cancer Institute (NCI), as well as $4.2 M (direct costs) in non-peer-reviewed funding. The focused development of MMC during the past 5 years provides the requisite infrastructure and knowledge base to forge translational research interactions within our own Cancer Center and with other Cancer Centers. A major strength of the Program over the past 5 years has been the expansion of research into mechanisms of metastasis and epigenetic signaling, as well as the new development of chemical approaches in cancer research. In summary, the MMC Program has a major impact on all components of the UCCCC as the primary driver of basic scientific discovery in molecular mechanisms of cancer using systems approaches, model organisms and primary human tumor samples. The interactions of MMC Program members with other UCCCC faculty through intra- and interprogrammatic collaborations further enable the key scientific steps needed for the discovery and development of promising therapies. Moving forward, MMC Program leadership recognizes new opportunities by leveraging our growing strengths especially in chemical biology, tumor metabolism, tumor microenvironment and immunology, and cancer metastasis, with the overarching goal of increasing successful basic science-clinical partnerships in these areas.

View original record on NIH RePORTER →